Technical Challenges Sample Clauses

Technical Challenges. To facilitate the process of negotiating security SLAs with different potential service providers, to make the comparison of different service offerings simpler, and to simplify the commitment phase of the service lifecycle, there is a need for common industry standards and corresponding templates for machine-readable agreements [1]. However, there are no such templates for security SLAs available today. Establishing a security SLA is not sufficient in itself; the agreed terms need to be monitored and controlled as well. However, monitoring and controlling security terms are inherently difficult. While other QoS aspects, such as the ser- vice availability, can easily be measured and controlled by the users themselves, security tends to be more difficult to monitor. One reason is the nature of ser- vice oriented architectures, which are designed to hide the inner workings of the services from the user, exposing only their APIs to the developers. Another rea- son is that the security requirements are often stated in terms of what should not happen, making it difficult to verify that the preventive mechanisms works as intended, until a breach has already occurred. In addition, the really clever attacks often go unnoticed.
AutoNDA by SimpleDocs
Technical Challenges. The challenge, constrained by economics and time, is to produce a finished genome sequence at a cost of under $0.10 per base at a rate of 600 Mb per year, in order to complete the genome for under $300 million dollars in a five-year period. Physical maps of the genome are now estimated to contribute less than 1 penny per base to the finished sequence cost (Lander et al., 1995) and to be nearly complete in time for the start of large scale sequencing of the human genome. This leaves $0.09 per base to go from the physical map to assembled and finished sequence. The most successful high-throughput DNA sequencing centers in the world are currently Principal Investigator/Program Director (Last, first, middle): Went, Gregory T. ---------------- -------------------------------------------------------------------------------- producing C. elegans sequence from physical maps at $0.50 per finished base at a rate of 10 Mb/year (Sulston et al., 1992; Wilson et al., 1994 ). The rate and cost of sequencing complete bacterial genomes and yeast chromosomes is comparable. To meet the HGP goals, it is necessary to increase the rate of production of finished sequence 60-fold while decreasing the cost 5-fold over these current projects. The logistical concerns of genome-scale DNA sequencing are essentially those derived from the need to increase throughput and reduce cost. This can only be done by improved technology integration and automation. Historically, the introduction of fluorescent four color sequencing into the life science research market enabled the sequencing of individual clones, small contiguous regions, and, when pushed to the limits of the original technology, the sequencing of the first complete bacterial genome (Fleischmann et al., 1995). An early 4-dye commercial instrument produced by Applied Biosystems, Inc., the ABI 373, and its subsequent replacement, the 377, were not designed with the logistics of large scale genomic sequencing in mind. Specifically, these instruments were not designed to efficiently integrate into a "factory environment" consisting primarily of robotic sample handling automated within an informatics framework.
Technical Challenges. Information technology together with enterprise systems and electronic commerce have supported large-scale business transformations, and forced firms to change their structures and functionality as well as their business strategies. Information technological developments help organizations in developing, capturing, storing and transforming the digital information. IT advancement makes it possible to share information within different units of organizations as well as across the organizations. But still organizations are facing problems how to share information across the supply chain. Today’s organizations have multiple information systems for multiple purposes. While facing different information related problems organizations adopt information system that is best in resolving that problem. According to [21] while implementing ERP systems, companies were forced with two approaches: 1) to change the software to fit the organization or 2) to change the organization to fit the process. Another strategy is “best of breed” approach, in which organizations adopt ERP modules from different vendors to meet their goals. Xxxxxxxxxxxxxx et al. in 2001 conducted a research on ERP and application integration. They found integration extremely difficult. They suggest that it is better to fit ERP package rather than try to customize it [22]. Many organizations go for “best of breed” approach, and as a result, many autonomous applications co-exist in companies alongside ERP. These autonomous systems use different identifiers for goods, assets and processes. Exchange of information between these autonomous systems within the organization and across supply chain is difficult in terms of formats, security, privacy, roles and semantic integration. While developing mashups developers are facing analogous challenges of deriving shared semantic meaning between heterogeneous data sets. Translation system between different dataset must be designed. During mapping reasonable assumptions have to be made (e.g. one data source have a model in which an address contains street-field, whereas another does not).
Technical Challenges. The use of RFID in the mining environment presents a number of challenges. These include read- ability due to long distances and unknown radio environment, uncertain orientation of transpon- ders, mechanical and electrical interference, and separation due to size and density. The subsec- tions below present conclusions and results on these technical challenges. The work performed in DISIRE on these matters link to work performed in the ePellet project, which was done by LTU in cooperation with LKAB. Thus, the sections below also contain results that were achieved in the frame of the ePellet project, as these to a high degree will affect the work and decisions taken in DISIRE.
Technical Challenges. 4.4.1 Use of the system in process outside the operative range Although the temperature range of the fiber optics is wide enough to measure with success sev- eral industrial process, the furnace temperature are difficult to be managed. If the temperature is in the 1000◦ C magnitude order, the use of fiber optic sensors becomes tricky. Working in a range close to the boundary of operative condition should also create problems because there wouldn´t be enough dynamic to evaluate temperature changes. In such cases the temperature variations are measured thought an indirect measurement system. This kind of application is based on the thermal identification of the interface between the process under observation and the measurement system to estimate the temperature in a system observing its thermal exchange with the environment. For the furnace temperature estimation the sensor could be placed on the external casing; in this case has to be known the isolation characteristics of the container. At this stage of the project there´s a workgroup active in the definition of the cross correlation be- tween the feasible acquiring system and the performances of the system. The fiber optic sensor technique is opening new possibilities that could lead to the possibility of better describe process performances to increase the whole efficiency. The final setup will be described in deliverable D8.1.
Technical Challenges. The use of RFID in the mining environment presents many challenges. These include readability due to long distances and unknown radio environment, uncertain orientation of transponders, mechanical and electrical interference, and separation due to size and density. The work performed in DISIRE on these matters link to work performed in the ePellet project, which was done by LTU in cooperation with LKAB. More details related to this work can be found in D3.1 which contains what were achieved in the frame of the ePellet project, as these to a high degree will affect the work and decisions taken in DISIRE. Tests were performed in Luleå harbour during early 2015. The tests were conducted at the location shown in Figure 17, the belt going up to “siktfickan” using a 3.D magnetic probe (Figure 18). Figure 17: The conveyor belt where the measurements were performed.
Technical Challenges. In Task 2.0, the project team will support regional deployment of CCUS programs by focusing on key technical challenges in the PCOR Partnership Initiative region related to stacked storage opportunities; storage resource potential with unconventional reservoirs; storage performance and subsurface integrity; monitoring, verification, and accounting (MVA) technology; and risk management . The Recipient will collaborate with various PCOR Partnership Initiative members to identify knowledge gaps and address regional challenges through targeted webinars, workshops, reports, and papers.
AutoNDA by SimpleDocs

Related to Technical Challenges

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Adverse Developments Promptly after the Lessee acquires knowledge thereof, written notice of:

  • Infringement Proceedings Each Party agrees to promptly notify the other Party of any unauthorized use of the other Party's Marks of which it has actual knowledge. Each Party will have the sole right and discretion to bring proceedings alleging infringement of its Marks or unfair competition related thereto; provided, however, that each Party agrees to provide the other Party with its reasonable cooperation and assistance with respect to any such infringement proceedings.

  • Patent Prosecution 7.1 UFRF shall diligently prosecute and maintain the Licensed Patents using counsel of its choice. UFRF shall provide Licensee with copies of all patent applications amendments, and other filings with the United States Patent and Trademark Office and foreign patent offices. UFRF will also provide Licensee with copies of office actions and other communications received by UFRF from the United States Patent and Trademark Office and foreign patent offices relating to Licensed Patents. Licensee agrees to keep such information confidential.

  • Commercialization Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to commercialize a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries. If Novartis commercializes a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries, Novartis will be deemed to satisfy all diligence obligations with respect to such Profile.

  • Arbitration Process Any arbitration will be conducted pursuant to the applicable rules (the “Arbitration Rules”) of the American Arbitration Association, as modified herein, to the extent such modifications are not prohibited by the Arbitration Rules. The arbitration will be conducted in Indianapolis, Indiana. The parties will select a single arbitrator, but in the event that the parties are unable to agree, the arbitrator will be appointed pursuant to the Arbitration Rules. The arbitrator will be a practicing attorney with significant expertise in litigating and/or presiding over cases involving the substantive legal areas involved in the dispute. The parties to the arbitration will not request, and the arbitrator will not order, that any discovery be taken or provided, including depositions, interrogatories or document requests, except to the extent the amount in controversy exceeds $50,000. The arbitration will be concluded within three months of the date the arbitrator is appointed. The arbitrator’s findings, reasoning, decision, and award will be stated in writing and based upon applicable law. Judgment on the arbitration award may be entered in any court having jurisdiction. In the event that the arbitration results in an award which imposes an injunction or contains a monetary award in excess of $100,000, the award will be reviewable on appeal initiated by filing notice of appeal with the AAA office within 30 days of the award, governed by the AAA Optional Appellate Arbitration Rules and conducted by a panel of three new arbitrators, ruling by majority, under the procedure for appointment from the national roster of arbitrators. Unless the applicable Arbitration Rules require otherwise, arbitration fees and costs will be shared equally by the claimant(s) and respondent(s), respectively, in any arbitration proceeding. Should the AAA be unavailable, unable or unwilling to accept and administer the arbitration of any claim under these arbitration provisions as written, the parties will agree on a substitute arbitration organization, such as JAMS, that will enforce the arbitration provisions as written. Because this Agreement memorializes a transaction in interstate commerce, the Federal Arbitration Act governs the interpretation and enforcement of these arbitration provisions. More information about arbitration, including the Arbitration Rules, is available at xxx.xxx.xxx or by calling 0-000-000-0000.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Reverse Engineering The Customer must not reverse assemble or reverse compile or directly or indirectly allow or cause a third party to reverse assemble or reverse compile the whole or any part of the software or any products supplied as a part of the Licensed System.

Time is Money Join Law Insider Premium to draft better contracts faster.